Zobrazeno 1 - 10
of 31
pro vyhledávání: ''
Autor:
Shannan L. Rossi, William S Lawrence, Sabrina Schrauf, Jessica A. Plante, Eryu Wang, Jason E. Comer, Scott C. Weaver, Katrin Ramsauer, Sasha R. Azar
Publikováno v:
The Journal of Infectious Diseases
Background Chikungunya virus (CHIKV) infection can result in chikungunya fever (CHIKF), a self-limited acute febrile illness that can progress to chronic arthralgic sequelae in a large percentage of patients. A new measles virus-vectored vaccine was
Publikováno v:
The Journal of infectious diseases. 219(Suppl_1)
The year 2018 marked the 100th anniversary of the deadliest event in human history. In 1918–1919, pandemic influenza spread globally and caused an estimated 50–100 million deaths associated with unexpected clinical and epidemiological features. T
Publikováno v:
The Journal of infectious diseases. 219(2)
Preexisting immunity to Zika virus (ZIKV) or dengue virus (DENV) may alter the course of their infection, and here we use robust mouse models to examine pathological outcomes following passive immunization, sequential cross-infection, or vaccination
Publikováno v:
The Journal of Infectious Diseases. 207:319-322
Chikungunya virus (CHIKV) is an alphavirus prevalent in tropical regions. It causes an acute febrile disease that, in elderly individuals and newborns, is often associated with severe complications. We previously reported the isolation and characteri
Autor:
Guiyun Li, David W. Scheifele, Marc Dionne, Suzana Sabaiduc, Nathalie Bastien, Naveed Z. Janjua, Martin Petric, Jennifer L. Gardy, Vladimir Gilca, Guy Boivin, Gaston De Serres, Yan Li, Danuta M. Skowronski, Dale Purych
Publikováno v:
The Journal of Infectious Diseases. 206:1852-1861
Background. Cases of infection due to a novel swine-origin variant of influenza A virus subtype H3N2 (H3N2v) have recently been identified in the United States, primarily among children. We estimate levels of cross-reactive antibody to H3N2v by age a
Autor:
Yuemei Hu, Qunying Mao, Yun-Tao Zhang, Kai Chu, Yuxiao Wang, Fengcai Zhu, Xiu-Ling Li, Pei Liu, Jingxin Li, Shiyuan Wang, Nianmin Shi, Fan-Yue Meng, Mingwei Wei, Zhenglun Liang, Hong Tao
Publikováno v:
The Journal of infectious diseases. 215(1)
BACKGROUND This study evaluated the 2-year efficacy, immunogenicity, and safety of the Vigoo enterovirus 71 (EV71) vaccine. METHOD In an initial phase 3 study, we randomly assigned healthy infants and children aged 6-35 months (ratio, 1:1) to receive
Autor:
Trina Racine, Gary P. Kobinger, Stéphane Pillet, Ami Patel, Jeffrey W. Turner, Xiangguo Qiu, Jason S. Richardson, Jane Ennis, Geoff Soule, Gary Wong
Publikováno v:
The Journal of infectious diseases. 212
Ebola virus (EBOV) causes lethal disease in up to 90% of EBOV-infected humans. Among vaccines, only the vesicular stomatitis virus platform has been successful in providing postexposure protection in nonhuman primates. Here, we show that an adjuvante
Autor:
John L. Sullivan, Gregory J. Babcock, Norman Hayes, Jeannette Guarner, Leatrice Vogel, Sherif R. Zaki, Anjeanette Roberts, William D. Thomas, Kanta Subbarao, Donna M. Ambrosino, Elaine W. Lamirande, Thomas C. Greenough
Publikováno v:
The Journal of Infectious Diseases
4 Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia Background. Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for the prevention of
Publikováno v:
The Journal of Infectious Diseases. 190:1084-1087
The safety and potential efficacy of interferon (IFN)-alpha2b were determined for 15 patients during an outbreak of meningoencephalitis due to St. Louis encephalitis (SLE) virus. Clinical and laboratory results were compared with those of 17 untreate
Autor:
Nancy J. Jensen, David I. Bernstein, Nigel Bourne, Greg Stroup, Mark R. Schleiss, Fernando J. Bravo
Publikováno v:
The Journal of Infectious Diseases. 189:1374-1381
Glycoprotein B (gB) has emerged as a subunit-vaccine candidate for congenital cytomegalovirus (CMV) infection, a major public health problem. The present study evaluated a cloned, recombinant gB vaccine in the guinea pig cytomegalovirus (GPCMV) model